|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Tuesday, March 17, 2020 |
|
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
| 新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社（NYSE American: NNVC） （以下「当社」）は、COVID-19を引き起こす現在の新型コロナウイルス（SARS-CoV-2）の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
|
NanoViricides公司冠狀病毒藥物開發更新 |
| NanoViricides公司（美國紐約證券交易所交易代碼NNVC）（公司）是基於新型納米藥學平台（公司）開發高效抗病毒治療方法的領先公司，目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發，現提供其工作相關更新。 more info >> |
|
|
NanoViricides公司冠状病毒药物开发更新 |
| NanoViricides公司（美国纽约证券交易所交易代码 NNVC）（公司）是基于新型纳米药学平台（公司）开发高效抗病毒治疗方法的领先公司，目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发，现提供其工作相关更新。 more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
富士通、世界最大のコネクティビティ関連展示会「MWC Barcelona 2025」に出展
Feb 5, 2025 14:30: JST
|
|
|
三菱造船、低圧液化CO₂内航輸送船の基本設計承認（AiP）を船級協会から取得
Feb 5, 2025 14:30: JST
|
|
|
トヨタ、米国ノースカロライナ州での車載用電池工場稼働開始
Feb 5, 2025 13:30: JST
|
|
|
トヨタ、上海市とカーボンニュートラルに関する包括的提携契約を締結
Feb 5, 2025 13:30: JST
|
|
|
トヨタ、2025年3月期 第3四半期決算を発表
Feb 5, 2025 13:30: JST
|
|
|
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 5, 2025 10:25 JST
|
|
|
Mallia Therapeutics 與 Northway Biotech 宣布合作生產可溶性 CD83 蛋白 用於脫髮治療
Feb 5, 2025 08:00 HKT/SGT
|
|
|
KKR、富士ソフトに対する第2回公開買付価格を1株9,850円に引き上げ
Feb 4, 2025 23:00: JST
|
|
|
QSEC-CEE 2025 Concludes with Breakthroughs in Quantum Cybersecurity
Feb 4, 2025 21:00: JST
|
|
|
QSEC-CEE 2025 Concludes with Breakthroughs in Quantum Cybersecurity
Feb 4, 2025 20:00 HKT/SGT
|
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Feb 4, 2025 18:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 4, 2025 18:41 JST
|
|
|
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 4, 2025 18:34 JST
|
|
|
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 4, 2025 17:38 JST
|
|
|
富士通、最適なモダナイゼーションの計画策定を生成AIで支援する「Fujitsu 資産分析・可視化サービス」を提供開始
Feb 4, 2025 10:40: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
